News from AAN 2026: BTKi
At the end of April, the annual meeting of the American Academy of Neurology (AAN) took place in Chicago. I had the opportunity to attend the congress on site and therefore want to summarize some
Continue reading
Tag: Fenebrutinib
News about Fenebrutinib
BTKi are considered to be the beacon of hope in the MS community, as they are supposed to specifically target and slow down the creeping parts of MS. BTKi are very small molecules that go
Continue reading
BTKi – the direction is right.
On November 10, 2025, Roche released a press release announcing that Fenebrutinib has reached its primary endpoint in the first Phase III trial (FENhance 2) of two similarly designed pivotal Phase III trials (FENhance 1
Continue reading
